Comparison of therapeutic effects
bleeding, PCOS, pain, RPOC, abortion
BLEEDING, STILL, DRUG SIDE EFFECTS, RETAINED PRODUCTS OF CONCEPTION, POLYCYSTIC OVARY SYNDROME, RETAINED PRODUCTS OF CONCEPTION
There was no significant difference between the three treatment groups regarding the amount of bleeding after the abortion(P = 0.627). Still, in the Misoprostol + Methylergometrine group, 80% of the patients were in the mild bleeding group. In contrast, in the two groups of Misoprostol + Oxytocin and Misoprostol alone, this amount was 63.33% and 53.33%, respectively(Table In terms of pain severity, there was a statistically significant difference between the three groups(p = 0.004). The group receiving Misoprostol + Methylergometrine had less pain intensity than the other two groups (Table In addition, no statistically significant difference was observed between the three groups regarding spotting after abortion (P = 0.894) (Table 
Abortion indications in three groups under study



*VAS: Visual Analogue Scale, * Chi-square test, significance level < 0.05
Minimum, maximum, and median of pain severity based on VAS scores in three groups under studyAssessing the rate of RPOC expulsion, no significant difference was seen before the intake of different medications(P = 0.434). However, a statistical difference was detected after patients’ exposure to these medications(P = 0.013). The mean rate of RPOC expulsion was in the Misoprostol + Oxytocin(9.68 ± 10.36) group, Misoprostol + Methylergometrine (11.73 ± 12.86), and Misoprostol groups (19.07 ± 14.31). As can be seen, the effectiveness of the drugs in the two drug groups combined with oxytocin and methylergometrine is higher compared to the misoprostol group alone (Table Finally, the outcomes demonstrated an 83.33% success rate in outpatient medical abortion patients treated with misoprostol alone. In contrast, those groups treated with misoprostol plus oxytocin and misoprostol plus methylergonovine illustrated a success rate of 93.33%. In addition, the results showed no statistically significant difference in drug side effects in the treatment groups under study (P = 0.329) (Table 
Comparison of retained products of conception (RPOC) and state of ovary before and after medical therapy in three groups under studyRPOC: Retained products of conception, PCOS: Polycystic ovary syndrome, *One-way ANOVA, * * independent t-test,* * * Chi-square test NA: Not applicable, significance level < 0.05